

[図1]

Study No. 370264




Fig. 1. Kaplan-Meier plot.

a) Start of administration in the control group and the EF-2001 group at 1.6 mg/kg/day for 17 days.
b) Start of administration in the EF-2001 group at 1.6 mg/kg/day for 10 days and 4.8 mg/kg/day for 10 days.
Significantly different from the control group (#; $p < 0.05$ by Generalized wilcoxon test).

[図2]

Study No. 370264




Fig. 2. Rectal temperature.
a): Start of administration in the control group and the EF-2001 group at 1.6 mg/kg/day for 17 days.
b): Start of administration in the EF-2001 group at 1.6 mg/kg/day for 10 days and 4.8 mg/kg/day for 10 days.
Significantly different from the control group (*; $p<0.05$).
Significantly different from the EF-2001 group at 1.6 mg/kg/day for 17 days (#; $p<0.05$).
Significantly different from the EF-2001 group at 1.6 mg/kg/day for 10 days (††; $p<0.01$).

[図3]

Study No. 37026-4




Fig. 3. Body weights.

a): Start of administration in the control group and the EF-2001 group at 1.6 mg/kg/day for 17 days.

b): Start of administration in the EF-2001 group at 1.6 mg/kg/day for 10 days and 4.8 mg/kg/day for 10 days.

[図4]

Study No. 370264





Fig. 4. Food consumption.

Significantly different from the control group (*: $p < 0.05$).

Administration began on 7 days before infection in the control group, the EF-2001 group at 1.6 mg/kg/day for 17 days.

a): Start of administration in the EF-2001 group at 1.6 mg/kg/day for 10 days and 4.8 mg/kg/day for 10 days.

Study No. 370262



a): Start of administration in the EF-2001 group at 1.6 mg/kg/day for 10 days and 4.8 mg/kg/day for 17 days.

[図6]

